Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
American Journal of Physiology. Heart and Circulatory Physiology|September 18, 2020
Proarrhythmic electrophysiological and structural remodeling in rheumatoid arthritisKiran Haresh Kumar Patel, Timothy Nicholas Jones, Susanne Sattler, et al.Pharmaceutical Research|March 13, 2025
Industry Perspectives on Implementation of Model Master File (MMF) Framework for Generics and Innovator Drugs: Opportunities, Challenges and Future OutlookSivacharan Kollipara, Markus Friden, Tycho Heimbach, et al.The AAPS Journal|March 28, 2023
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsVivek Purohit, Yeamin Huh, Jessica Wojciechowski, et al.CPT: Pharmacometrics & Systems Pharmacology|November 16, 2023
Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug developmentWei Gao, Jiang Liu, Blerta Shtylla, et al.Journal of Pharmacokinetics and Pharmacodynamics|March 3, 2024
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasisNikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, et al.Clinical Pharmacology in Drug Development|May 13, 2022
Bridging Efficacy of Tofacitinib Immediate-Release to Extended-Release Formulations for Treatment of Ulcerative Colitis: Application of a Model-Informed Drug Development ApproachArnab Mukherjee, Shinichi Tsuchiwata, Cheng Chang, et al.Current Alzheimer Research|May 8, 2014
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's diseaseElias M Schwam, Timothy Nicholas, Robert Chew, et al.CPT: Pharmacometrics & Systems Pharmacology|October 7, 2023
Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysisPhylinda L S Chan, Ravi Shankar P Singh, Donna S Cox, et al.Clinical Pharmacology in Drug Development|May 9, 2022
Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy VolunteersXiaoxing Wang, Pankaj Gupta, Bimal K Malhotra, et al.Clinical Pharmacology and Therapeutics|April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesArnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.Pageof 6